Nusinersen: Single-Centre Real-Life Experience in Type 1 Spinal Muscular Atrophy

Introduction: Nusinersen, an antisense oligonucleotide designed to treat spinal muscular atrophy, led to substantial motor milestone achievements in clinical trials. The aim of this study was to report the clinical outcome of children diagnosed with spinal muscular atrophy type 1 treated with nusin...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Andreia Lomba, Joana A. Ribeiro, Henriqueta Araújo, Vera Ribeiro, Núria Madureira, Filipe Palavra, Carmen Costa, Isabel Fineza
Formato: article
Lenguaje:EN
PT
Publicado: Sociedade Portuguesa de Pediatria 2021
Materias:
Acceso en línea:https://doaj.org/article/828fb533814c45c68d07e54b9f60eae3
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!